Before PSM, SGLT2i initiators were younger, with a longer disease duration, higher BMI and HbA1c, worse lipid profile, more prevalent retinopathy, and more concomitant use of insulin, but higher baseline eGFR and lower pre‐index date eGFR slope (Table 1). This evidence concerns the gene INS and retinal disorder.